Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism First-in-human findings with ...

Clinical data from independent investigator-initiated studies using [68Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with [¹77Lu]Lu-Pentix ...

Phase 2 Trial in Multiple Myeloma Nears Key ReadoutPreparing for Expansion into Sickle Cell Disease and Acute Myeloid ...

Barcelona-based Nanoligent, a biotechnology company specialised in the development of targeted nanodrugs for cancer treatment, has secured €12M in a new ...

In their quest for safe, mass-producible artificial blood, geneticists have long struggled. Our limited knowledge of genetic pathways that govern the development of blood has kept us from producing ...

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025Presented ...

The CXCR inhibitor market is expanding steadily as interest in targeted oncology and immuno-oncology treatments grows. Rising ...

Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development ...

Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in ...

The research team found that the supplementation of n-3 fatty acids significantly enhances lactation performance even in ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...